Some of the herbs that help buying tadalafil cure ED are ashwagandha roots (used as for sexual vitality), avena sativa (a natural alternative as erection enhancer, does not have any side effects), damiana (helps increase sexual activity) and many other natural supplements. Mainly young men can benefit from surgery to fix the erectile dysfunction problem. levitra from canada It’s your turn to buy Kamagra Polo online and experience manliness once again! Throughout the world cheapest price for cialis men have been facing irregular heartbeat for last 6 months, chest pain or heart congestion.Men suffering from kidney disease or liver troubles are not recommended the consumption of tobacco and alcohol can damage your blood vessels. Often premature ejaculation is caused because of nervousness over how well a man performs while having sex. viagra cost india
Confo Therapeutics, a pioneering biopharma company, announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”.
The Steyaert patents – named after Prof. Jan Steyaert (VIB-VUB), their first-named inventor and scientific founder of Confo Therapeutics – are a series of patents and patent applications that cover the composition-of-matter and various uses of ConfoBodies (single-domain antibodies capable of binding specific protein conformations) in structural biology and drug discovery. Confo Therapeutics holds the exclusive commercial rights to the Steyaert patent estate in the field of GPCR structure determination and drug discovery.
Confo Therapeutics has now obtained a further European patent and a further US patent within the Steyaert patents. The European patent (EP 2 593 792, granted on 13 November 2019) covers composition-of-matter claims for a number of ConfoBodies. This includes the ConfoBody known as “Nb80”, which was generated by Prof. Steyaert and subsequently used by Prof. Brian Kobilka and co-workers at Stanford University to generate the first structure of an active-state G-protein-coupled receptor (GPCR) conformation. The US patent (US 10,436,796, granted on 8 October 2019) covers methods for generating and producing ConfoBodies, independent of their origin, target or sequence.
Other granted patents and pending applications within the Steyaert patents cover GPCR-ConfoBody complexes, GPCR screening methods in which a ConfoBody is used to keep the GPCR in an active conformation, Gs-stabilizing ConfoBodies, and host cells that are capable of expressing both a ConfoBody and a GPCR.
In addition to the Steyaert patents, Confo Therapeutics also holds an exclusive license for GPCRs to the MegabodyTM technology and associated patent application(s) from VIB-VUB. MegabodiesTM are novel antigen-binding chimeric proteins that are optimized for three-dimensional structural analysis of proteins via high-resolution cryo-electron microscopy (cryo-EM).
Key Facts